Olimestra Tương tác

Effects of other medicinal products on olmesartan medoxomil: Other antihypertensive medications: The blood pressure-lowering effect of olmesartan medoxomil can be increased by concomitant use of other antihypertensive medications.
ACE-inhibitors, angiotensin II receptor blockers, or aliskiren: the combined use of ACE-inhibitors, angiotensin II receptor blockers, or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalemia, and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent.
Potassium supplements and potassium-sparing diuretics: concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium. Such concomitant use is therefore not recommended.
Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs (including acetylsalicylic acid at doses >3 g/day and also COX-2 inhibitors) and angiotensin-II receptor antagonists may act synergistically by decreasing glomerular filtration. The risk of the concomitant use of NSAIDs and angiotensin II antagonists is the occurrence of acute renal failure. Monitoring of renal function at the beginning of treatment should be recommended.
Additionally, concomitant treatment can reduce the antihypertensive effect of angiotensin II receptor antagonists, leading to their partial loss of efficacy.
Bile acid sequestering agent colesevelam: Concurrent administration of the bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan and reduces t½. Administration of olmesartan medoxomil at least 4 hours before colesevelam hydrochloride decreased the drug interaction effect. Administering olmesartan medoxomil at least 4 hours before the colesevelam hydrochloride dose should be considered.
Other compounds: After treatment with an antacid (aluminum magnesium hydroxide), a modest reduction in the bioavailability of olmesartan was observed. Coadministration of warfarin and digoxin did not affect the pharmacokinetics of olmesartan.
Effects of olmesartan medoxomil on other medicinal products: Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin-converting enzyme inhibitors and angiotensin II antagonists. Therefore use of olmesartan medoxomil and lithium in combination is not recommended. If the use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.
Other compounds: Compounds that have been investigated in specific clinical studies in healthy volunteers include warfarin, digoxin, an antacid (magnesium aluminum hydroxide), hydrochlorothiazide, and pravastatin. No clinically relevant interactions were observed and in particular, olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics of digoxin.